Friday, April 8, 2011
Targacept Inc., of Winston-Salem, N.C., reported data from a Phase II trial showing that its schizophrenia candidate TC-5619 caused statistically significant superiority over placebo for cognitive dysfunction in schizophrenia and negative symptoms of schizophrenia. In the trial, 185 patients with schizophrenia, having stable psychotic symptoms and taking an approved atypical antipsychotic medication, received TC-5619 or placebo in addition to their antipsychotic, for 12 weeks. The drug was well tolerated with nausea as its most frequent adverse event.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.